David E. Allison

2.1k total citations
22 papers, 1.6k citations indexed

About

David E. Allison is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David E. Allison has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David E. Allison's work include Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). David E. Allison is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). David E. Allison collaborates with scholars based in United States, Switzerland and France. David E. Allison's co-authors include Mark X. Sliwkowski, Beth Y. Karlan, Michael S. Gordon, W. T. Edmondson, David S. Mendelson, David B. Agus, Janet Clarke, Kathleen McKeever, Kelly M. Flagella and Noël Dybdal and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Endocrinology.

In The Last Decade

David E. Allison

22 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Allison United States 15 857 825 648 254 183 22 1.6k
Songwon Seo South Korea 23 508 0.6× 432 0.5× 276 0.4× 238 0.9× 294 1.6× 67 1.7k
Jörg Nährig Germany 27 565 0.7× 650 0.8× 636 1.0× 120 0.5× 486 2.7× 51 2.1k
David Mauro United States 18 486 0.6× 554 0.7× 609 0.9× 429 1.7× 295 1.6× 76 2.1k
Nori Nakamura Japan 31 914 1.1× 716 0.9× 1.2k 1.9× 197 0.8× 464 2.5× 120 2.9k
Bogdanova Ti Ukraine 35 1.1k 1.3× 866 1.0× 792 1.2× 156 0.6× 342 1.9× 94 3.5k
L F Meisner United States 19 347 0.4× 692 0.8× 873 1.3× 64 0.3× 246 1.3× 33 1.9k
Peter Dall Germany 30 119 0.1× 805 1.0× 1.1k 1.7× 215 0.8× 140 0.8× 97 2.5k
JA Ledermann United Kingdom 24 311 0.4× 904 1.1× 437 0.7× 142 0.6× 439 2.4× 69 2.0k
J. D. Boice United States 14 725 0.8× 517 0.6× 256 0.4× 41 0.2× 347 1.9× 21 2.2k
Youn Soo Lee South Korea 26 207 0.2× 522 0.6× 671 1.0× 138 0.5× 406 2.2× 130 2.2k

Countries citing papers authored by David E. Allison

Since Specialization
Citations

This map shows the geographic impact of David E. Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Allison more than expected).

Fields of papers citing papers by David E. Allison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Allison. The network helps show where David E. Allison may publish in the future.

Co-authorship network of co-authors of David E. Allison

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Allison. A scholar is included among the top collaborators of David E. Allison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Allison. David E. Allison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, Kelong, Mathilde Marchand, Angelica Quartino, et al.. (2016). Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemotherapy and Pharmacology. 78(2). 341–351. 55 indexed citations
2.
3.
Bai, Shuang, Karin Jorga, Xin Yan, et al.. (2012). A Guide to Rational Dosing of Monoclonal Antibodies. Clinical Pharmacokinetics. 51(2). 119–135. 127 indexed citations
4.
Li, Jing, et al.. (2012). Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. Cancer Chemotherapy and Pharmacology. 71(3). 575–580. 29 indexed citations
5.
Khawli, Leslie A., Ryan Hutchinson, Jihong Yang, et al.. (2010). Charge variants in IgG1. mAbs. 2(6). 613–624. 340 indexed citations
6.
Yan, Xin, Tanyifor M. Tohnya, Ronald Herbst, et al.. (2008). Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma. Journal of Clinical Oncology. 26(15_suppl). 2525–2525. 5 indexed citations
7.
Gordon, Michael S., Daniela Matei, Carol Aghajanian, et al.. (2006). Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status. Journal of Clinical Oncology. 24(26). 4324–4332. 187 indexed citations
8.
Adams, Camellia, David E. Allison, Kelly M. Flagella, et al.. (2005). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunology Immunotherapy. 55(6). 717–727. 241 indexed citations
9.
Allison, David E., et al.. (2005). Pharmacokinetics (PK) of pertuzumab (rhuMAb 2C4) in phase II studies of ovarian, breast, prostate, and lung cancers. Journal of Clinical Oncology. 23(16_suppl). 2532–2532. 7 indexed citations
10.
Agus, David B., Michael S. Gordon, Charles Taylor, et al.. (2005). Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology. 23(11). 2534–2543. 304 indexed citations
11.
Tótpál, Klára, Mark X. Sliwkowski, Lisa Crocker, et al.. (2003). Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. 44. 150. 20 indexed citations
12.
13.
Baly, Deborah L., Richard Horuk, Daniel G. Yansura, et al.. (1998). A His19 to Ala Mutant of Melanoma Growth-Stimulating Activity Is a Partial Antagonist of the CXCR2 Receptor. The Journal of Immunology. 161(9). 4944–4949. 10 indexed citations
14.
Baly, D L, David E. Allison, Lynne Krummen, et al.. (1993). Development of a specific and sensitive two-site enzyme-linked immunosorbent assay for measurement of inhibin-A in serum.. Endocrinology. 132(5). 2099–2108. 21 indexed citations
15.
Woodruff, Teresa K., Lynne Krummen, Rebecca Lyon, et al.. (1993). Pharmacokinetic profile of recombinant human (rh) inhibin A and activin A in the immature rat. I. Serum profile of rh-inhibin A and rh-activin A in the immature female rat.. Endocrinology. 132(2). 715–724. 17 indexed citations
16.
Singh, Prithipal, et al.. (1989). Field evaluation of an enzyme immunoassay for detection of trichinellosis in hogs in a high volume north Carolina abattoir.. 439–444. 11 indexed citations
17.
Allison, David E., et al.. (1977). A new approach to estimate fatigue crack delay due to a single cycle overload. Engineering Fracture Mechanics. 9(3). 647–654. 8 indexed citations
18.
Allison, David E., et al.. (1976). The application of fractional calculus to estimate the delay cycles due to a single overload. International Journal of Fracture. 12(3). 491–494. 1 indexed citations
19.
Shapiro, Joseph, W. T. Edmondson, & David E. Allison. (1971). CHANGES IN THE CHEMICAL COMPOSITION OF SEDIMENTS OF LAKE WASHINGTON, 1958–1970. Limnology and Oceanography. 16(2). 437–452. 59 indexed citations
20.
Edmondson, W. T. & David E. Allison. (1970). RECORDING DENSITOMETRY OF X‐RADIOGRAPHS FOR THE STUDY OF CRYPTIC LAMINATIONS IN THE SEDIMENT OF LAKE WASHINGTON. Limnology and Oceanography. 15(1). 138–144. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Songwon Seo Breakdown of academic impact, for papers by Jörg Nährig Breakdown of academic impact, for papers by David Mauro Breakdown of academic impact, for papers by Nori Nakamura Breakdown of academic impact, for papers by Bogdanova Ti Breakdown of academic impact, for papers by L F Meisner Breakdown of academic impact, for papers by Peter Dall Breakdown of academic impact, for papers by JA Ledermann Breakdown of academic impact, for papers by J. D. Boice Breakdown of academic impact, for papers by Youn Soo Lee
Rankless by CCL
2026